Australian researchers bring Ross River virus vaccine a step closer

A VACCINE protecting against Ross River virus will go into a phase III trial in Australia this year.An earlier trial in almost 400 healthy adults showed the candidate vaccine was “well tolerated”, with 93% of participants producing neutralising antibodies within 21 days of a third injection, according to Associate Professor John Aaskov from the Queensland University of Technology.

Professor Aaskov presented details of his research at the Australasian Society for Infectious Diseases annual conference in Lorne, Victoria, last week.

Currently, there is no licensed vaccine against Ross River virus, which is endemic in Australia and the South Pacific.